A detailed history of Federated Hermes, Inc. transactions in Insmed Inc stock. As of the latest transaction made, Federated Hermes, Inc. holds 42,983 shares of INSM stock, worth $3.03 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
42,983
Previous 10,063 327.14%
Holding current value
$3.03 Million
Previous $674,000 365.43%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$62.0 - $79.01 $2.04 Million - $2.6 Million
32,920 Added 327.14%
42,983 $3.14 Million
Q2 2024

Aug 08, 2024

BUY
$22.0 - $69.71 $219,538 - $695,636
9,979 Added 11879.76%
10,063 $674,000
Q1 2024

May 14, 2024

SELL
$25.72 - $29.94 $668 - $778
-26 Reduced 23.64%
84 $2,000
Q4 2023

Jan 31, 2024

SELL
$23.42 - $31.74 $384,860 - $521,583
-16,433 Reduced 99.34%
110 $3,000
Q3 2023

Nov 13, 2023

BUY
$19.86 - $26.93 $328,543 - $445,502
16,543 New
16,543 $417,000
Q3 2019

Nov 14, 2019

SELL
$15.49 - $25.78 $3.86 Million - $6.42 Million
-249,177 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$23.0 - $32.19 $2.04 Million - $2.86 Million
-88,793 Reduced 26.27%
249,177 $6.38 Million
Q1 2019

May 10, 2019

BUY
$13.91 - $31.15 $4.7 Million - $10.5 Million
337,970 New
337,970 $9.83 Million
Q2 2018

Aug 10, 2018

SELL
$20.0 - $29.72 $20,320 - $30,195
-1,016 Closed
0 $0
Q1 2018

May 09, 2018

SELL
$21.69 - $32.99 $944,577 - $1.44 Million
-43,549 Reduced 97.72%
1,016 $23,000
Q4 2017

Feb 14, 2018

BUY
$26.43 - $31.78 $761,818 - $916,026
28,824 Added 183.11%
44,565 $0
Q3 2017

Nov 13, 2017

BUY
$11.61 - $31.21 $182,753 - $491,276
15,741
15,741 $491,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.56B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.